Nguyen K, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22:2142–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dördelmann M, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94(1209–1217):47.

Google Scholar 

DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–53.

Article  CAS  PubMed  Google Scholar 

Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11:1096–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaspers GJ, Veerman AJ, Popp-Snijders C, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1996;27:114–21.

Article  CAS  PubMed  Google Scholar 

Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5(2):202–7.

Article  CAS  PubMed  Google Scholar 

Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19(4):269–75.

Article  CAS  PubMed  Google Scholar 

Veerman AJ, Hählen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14(3):911–8.

Article  CAS  PubMed  Google Scholar 

Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. Cancer Res. 1985;45:6482–6.

CAS  PubMed  Google Scholar 

Tissing WJ, Meijerink JP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 2003;17:17–25.

Article  CAS  PubMed  Google Scholar 

. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809–17. Landmark paper highlighting higher EFS and less CNS relapse with dexamethasone.

Article  CAS  PubMed  Google Scholar 

. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129:734–45. Landmark paper highlighting superiority of dexamethasone over prednisone resulting in early closure of randomization.

Article  CAS  PubMed  Google Scholar 

. Vrooman LM, Neuberg DS, Stevenson KE, Supko JG, Sallan SE, Silverman LB. Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: results from DFCI-ALL Consortium Protocol 00-01. Blood (ASH Annual Meeting Abstracts). 2009;114:321. Landmark paper demonstrating that higher EFS is even observed when dexamethasone is used only after induction therapy and can abrogate the adversity of high-risk disease.

Google Scholar 

. Schrappe M, Zimmermann M, Moricke A, et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 Patients (Trial AIEOP-BFM ALL 2000). Blood (ASH Annual Meeting Abstracts). 2008;112:7. Landmark study of higher dose prednisone vs dexamethasone during induction demonstrating overall reduced relapse risk and improved outcomes with dexamethasone though offset but risk of life-threatening infection, specifically patients aged 10 or older.

Google Scholar 

Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–14.

Article  CAS  PubMed  Google Scholar 

Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077–84.

Article  CAS  PubMed  Google Scholar 

Möricke A, Zimmermann M, Stanulla M, Biondi A, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101–12.

Article  PubMed  Google Scholar 

Reiter A, Schrappe M, Parwaresch R, Henze G, Müller-Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage–a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 1995;13:359–72.

Article  CAS  PubMed  Google Scholar 

Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, Freitas JR, et al. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer. 2006;95:1537–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beesley AH, Weller RE, Senanayake S, Welch M, Kees UR. Receptor mutation is not a common mechanism of naturally occurring glucocorticoid resistance in leukaemia cell lines. Leuk Res. 2009;33:321–5.

Article  CAS  PubMed  Google Scholar 

Hunger S. P Glucocorticoid Selection for Pediatric ALL. Blood. 2016;127:2049–51.

Article  CAS  PubMed  Google Scholar 

Borin C, Pieters T, Serafin V, Ntziachristos P. Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia. HemaSphere. 2023;7(7):e916.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao J, Liu WJ. Prognostic Value of the Response to Prednisone for Children with Acute Lymphoblastic Leukemia: A Meta-Analysis. Eur Rev Med Pharmacol Sci. 2018;22:7858–66.

CAS  PubMed  Google Scholar 

Van der Zwet JCG, Smits W, Buijs-Gladdines JGCAM, Pieters R, Meijerink JPP. Recurrent NR3C1 Aberrations at First Diagnosis Relate to Steroid Resistance in Pediatric T-Cell Acute Lymphoblastic Leukemia Patients. HemaSphere. 2020;5:e513.

Article  PubMed  PubMed Central  Google Scholar 

Caratti G, Matthews L, Poolman T, Kershaw S, Baxter M, Ray D. Glucocorticoid Receptor Function in Health and Disease. Clin. Endocrinol. 2015;83:441–448. 26.

Article  CAS  Google Scholar 

Nick ZLU, Cidlowski JA. The Origin and Functions of Multiple Human Glucocorticoid Receptor Isoforms. Ann N Y Acad Sci. 2004;1024:102–23.

Article  Google Scholar 

Lu NZ, Cidlowski JA. Translational Regulatory Mechanisms Generate N-Terminal Glucocorticoid Receptor Isoforms with Unique Transcriptional Target Genes. Mol Cell. 2005;18:331–42.

Article  CAS  PubMed  Google Scholar 

Cain DW, Cidlowski JA. Specificity and Sensitivity of Glucocorticoid Signaling in Health and Disease. Best Pract Res Clin Endocrinol Metab. 2015;29:545–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beger C, Gerdes K, Lauten M, Tissing WJE, Fernandez-Munoz I, Schrappe M, Welte K. Expression and Structural Analysis of Glucocorticoid Receptor Isoform Gamma in Human Leukaemia Cells Using an Isoform-Specific Real-Time Polymerase Chain Reaction Approach. Br J Haematol. 2003;122:245–52.

Article  CAS  PubMed  Google Scholar 

Jing D, Bhadri VA, Beck D, Thoms JAI, Yakob NA, Wong JWH, Knezevic K, Pimanda JE, Lock RB. Opposing Regulation of BIM and BCL2 Controls Glucocorticoid-Induced Apoptosis of Pediatric Acute Lymphoblastic Leukemia Cells. Blood. 2015;125:273–83.

Article  CAS  PubMed  Google Scholar 

Malyukova A, Brown S, Papa R, O’Brien R, Giles J, Trahair TN, Dalla PL, Sutton R, Liu T, Haber M, et al. FBXW7 Regulates Glucocorticoid Response in T-Cell Acute Lymphoblastic Leukaemia by Targeting the Glucocorticoid Receptor for Degradation. Leukemia. 2013;27:1053–62.

Article  CAS  PubMed